{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:58:02Z","timestamp":1794272282215,"version":"4.9.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.critrevonc.2025.104747","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T18:31:40Z","timestamp":1745692300000},"page":"104747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challenges"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-675X","authenticated-orcid":false,"given":"Pablo","family":"Jim\u00e9nez-Labaig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Lorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gurizzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Kinloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Metcalf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"O\u00b4leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Bra\u00f1a","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104747_bib1","unstructured":"Head and Neck Cancers NCCN Guidelines. Published online February 29, 2024a."},{"key":"10.1016\/j.critrevonc.2025.104747_bib2","unstructured":"Results Posted | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | ClinicalTrials.gov. Accessed August 2, 2024b. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03749460?tab=results\u3009."},{"key":"10.1016\/j.critrevonc.2025.104747_bib3","doi-asserted-by":"crossref","unstructured":"A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer | Clinical Cancer Research | American Association for Cancer Research. Accessed August 2, 2024c. \u3008https:\/\/aacrjournals.org\/clincancerres\/article\/26\/4\/837\/83019\/A-Phase-II-Trial-of-Pembrolizumab-and-Vorinostat\u3009.","DOI":"10.1158\/1078-0432.CCR-19-2214"},{"key":"10.1016\/j.critrevonc.2025.104747_bib4","doi-asserted-by":"crossref","unstructured":"Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers | The Oncologist | Oxford Academic. Accessed August 4, 2024d. \u3008https:\/\/academic.oup.com\/oncolo\/article\/29\/6\/e779\/6583386\u3009.","DOI":"10.1093\/oncolo\/oyac080"},{"key":"10.1016\/j.critrevonc.2025.104747_bib5","unstructured":"Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Salivary Duct Carcinoma | Journal of Clinical Oncology. Accessed August 7, 2024e. \u3008https:\/\/ascopubs.org\/doi\/pdf\/10.1200\/JCO.18.00545\u3009."},{"key":"10.1016\/j.critrevonc.2025.104747_bib6","unstructured":"Study Details | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | ClinicalTrials.gov. Accessed September 16, 2024f. \u3008https:\/\/clinicaltrials.gov\/study\/NCT01969578\u3009."},{"key":"10.1016\/j.critrevonc.2025.104747_bib7","unstructured":"Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place | npj Precision Oncology. Accessed September 15, 2024g. \u3008https:\/\/www.nature.com\/articles\/s41698-023-00487-5\u3009."},{"key":"10.1016\/j.critrevonc.2025.104747_bib8","doi-asserted-by":"crossref","unstructured":"Abstract CT178: GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study | Cancer Research | American Association for Cancer Research. Accessed August 4, 2024. \u3008https:\/\/aacrjournals.org\/cancerres\/article\/83\/8_Supplement\/CT178\/725282\/Abstract-CT178-GQ1001-A-next-generation-HER2\u3009.","DOI":"10.1158\/1538-7445.AM2023-CT178"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104747_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2019.09.036","article-title":"The Phase 1\/2 ACCEPT trial: concurrent cetuximab and intensity modulated radiation therapy with carbon ion boost for adenoid cystic carcinoma of the head and neck","volume":"106","author":"Adeberg","year":"2020","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104747_bib10","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non\u2013adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9619","key":"10.1016\/j.critrevonc.2025.104747_bib11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(08)60505-X","article-title":"EQUATOR: reporting guidelines for health research","volume":"371","author":"Altman","year":"2008","journal-title":"Lancet Lond. Engl."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104747_bib12","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S1470-2045(14)71153-2","article-title":"Accepting risk in the acceleration of drug development for rare cancers","volume":"16","author":"Ashley","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/annonc\/mdv547","article-title":"Access to innovative oncology medicines in Europe","volume":"27","author":"Bergmann","year":"2016","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104747_bib14","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.4161\/cc.4.12.2259","article-title":"Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance","volume":"4","author":"Blagosklonny","year":"2005","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104747_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","article-title":"Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative","volume":"51","author":"Bogaerts","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104747_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2021.10.033","article-title":"Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer","volume":"161","author":"Van Boxtel","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104747_bib17","first-page":"1169","article-title":"Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms","volume":"24","author":"Brill","year":"2011","journal-title":"Mod. Pathol. J. U S Can. Acad. Pathol. Inc."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104747_bib18","article-title":"A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic salivary gland cancers (R\/M SGCs)","volume":"39","author":"Burman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104747_bib19","unstructured":"Cancer Facts & Figures 2023 [Internet]. Cancer.org. Accessed December 26,2023. Available from \u3008https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2023-cancer-facts-figures.html\u3009."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104747_bib20","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/cncr.22647","article-title":"Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland","volume":"109","author":"Carrillo","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdu459","article-title":"Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper","volume":"26","author":"Casali","year":"2015","journal-title":"Ann. Oncol."},{"issue":"8_ement","key":"10.1016\/j.critrevonc.2025.104747_bib22","article-title":"Abstract CT165: Phase II study of nivolumab and ipilimumab for treatment of metastatic\/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors","volume":"83","author":"Chae","year":"2023","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104747_bib23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC","volume":"23","author":"Chau","year":"2012","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104747_bib24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for thE Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"41","key":"10.1016\/j.critrevonc.2025.104747_bib25","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1200\/EDBK_325885","article-title":"Taking aim at the undruggable","author":"Coleman","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.critrevonc.2025.104747_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1032471","article-title":"Salivary gland cancers in elderly patients: challenges and therapeutic strategies","volume":"12","author":"Colombo","year":"2022","journal-title":"Front Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104747_bib27","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro-Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104747_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/nop\/npae001","article-title":"Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: a potential model for rare diseases","volume":"11","author":"Dhaenens","year":"2024","journal-title":"Neuro-Oncol. Pr."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104747_bib29","article-title":"Phase II study of dovitinib (TKI258) in patients with progressive metastatic adenoid cystic carcinoma","volume":"31","author":"Dillon","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104747_bib30","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.ijrobp.2019.06.292","article-title":"Prospective Phase II Study of Concurrent Chemoradiotherapy in High-risk Malignant Salivary Gland Tumors","volume":"105","author":"Dou","year":"2019","journal-title":"Int J. Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104747_bib31","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers13040679","article-title":"Diagnosed with a rare cancer: experiences of adult sarcoma survivors with the healthcare system\u2014results from the SURVSARC study","volume":"13","author":"Drabbe","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib32","article-title":"786 Intratumorally administered CV8102 in patients with advanced solid tumors: preliminary results from ongoing expansion part in study 008","volume":"10","author":"Eigentler","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","article-title":"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma","volume":"38","author":"Even","year":"2020","journal-title":"Invest N. Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104747_bib34","article-title":"NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)","volume":"2","author":"Fayette","year":"2023","journal-title":"BMJ Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104747_bib35","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","article-title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","volume":"29","author":"Ferrarotto","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104747_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.6046","article-title":"Results of ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)","author":"Ferrarotto","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104747_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","article-title":"Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors","volume":"35","author":"Ferrarotto","year":"2017","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104747_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.02221","article-title":"Phase II clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma","author":"Ferrarotto","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2008.10.031","article-title":"Lessons learned from independent central review","volume":"45","author":"Ford","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104747_bib40","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104747_bib41","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104747_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hed.20327","article-title":"Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group","volume":"28","author":"Gilbert","year":"2006","journal-title":"Head. Neck"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104747_bib43","doi-asserted-by":"crossref","first-page":"32918","DOI":"10.18632\/oncotarget.16464","article-title":"A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma","volume":"8","author":"Goncalves","year":"2017","journal-title":"Oncotarget"},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104747_bib44","article-title":"PACSA: phase II study of pazopanib in patients with progressive recurrent or metastatic (R\/M) salivary gland carcinoma (SGC)","volume":"34","author":"Guigay","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104747_bib45","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. a phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104747_bib46","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1158\/1078-0432.CCR-23-1030","article-title":"A phase II trial of rivoceranib, an oral vascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma","volume":"29","author":"Hanna","year":"2023","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104747_bib47","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1002\/cncr.33036","article-title":"Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer","volume":"126","author":"Hanna","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104747_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105366","article-title":"A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma","volume":"119","author":"Hanna","year":"2021","journal-title":"Oral. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104747_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/nop\/npae035","article-title":"Platform trials for rare cancers\u2014a complex innovation to accelerate knowledge","volume":"11","author":"Hau","year":"2024","journal-title":"Neuro-Oncol. Pr."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104747_bib50","doi-asserted-by":"crossref","first-page":"20299","DOI":"10.1002\/cam4.6589","article-title":"Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial","volume":"12","author":"Hernando-Calvo","year":"2023","journal-title":"Cancer Med"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104747_bib51","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ejca.2008.08.014","article-title":"Phase II study on gemcitabine in recurrent and\/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)","volume":"44","author":"Herpen","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104747_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO\u2013european reference network on rare adult solid cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up","volume":"7","author":"van Herpen","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104747_bib53","unstructured":"Home. STAMPEDE. Accessed September 15, 2024. \u3008https:\/\/www.stampedetrial.org\/\u3009."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104747_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hed.24933","article-title":"Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and\/or metastatic salivary gland cancer of the head and neck","volume":"40","author":"Hong","year":"2018","journal-title":"Head. Neck"},{"key":"10.1016\/j.critrevonc.2025.104747_bib55","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-0455","article-title":"Apalutamide and goserelin for androgen receptor\u2013positive salivary gland carcinoma: a phase ii nonrandomized clinical trial, YATAGARASU","author":"Honma","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104747_bib56","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hed.23664","article-title":"Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: results of a phase II clinical trial","volume":"37","author":"Hoover","year":"2015","journal-title":"Head. Neck"},{"key":"10.1016\/j.critrevonc.2025.104747_bib57","doi-asserted-by":"crossref","first-page":"vi335","DOI":"10.1093\/annonc\/mdw376.24","article-title":"Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: ontario clinical oncology group DOVE trial","volume":"27","author":"Hotte","year":"2016","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104747_bib58","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.35103","article-title":"A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104)","volume":"130","author":"Ho","year":"2024","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104747_bib59","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.22.00229","article-title":"Phase II study of enzalutamide for patients with androgen receptor\u2013positive salivary gland cancers (Alliance A091404)","volume":"40","author":"Ho","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104747_bib60","article-title":"Phase II study of regorafenib in progressive, recurrent\/metastatic adenoid cystic carcinoma","volume":"34","author":"Ho","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104747_bib61","unstructured":"ICTRP Search Portal. Accessed September 16, 2024. \u3008https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2011210017\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104747_bib62","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"A phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head. Neck"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104747_bib63","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.ijrobp.2024.01.172","article-title":"Efficacy and safety of surufatinib for recurrent or metastatic malignant salivary gland tumors: an open-label, single-arm, phase II study","volume":"118","author":"Jiang","year":"2024","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104747_bib64","article-title":"A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing","volume":"42","author":"Ji","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104747_bib65","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","article-title":"Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma","volume":"27","author":"Kang","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104747_bib66","article-title":"Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma","volume":"38","author":"Keam","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104747_bib67","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cncr.29401","article-title":"Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma","volume":"121","author":"Keam","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104747_bib68","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-022-01820-1","article-title":"TKI treatment sequencing in advanced gastrointestinal stromal tumors","volume":"83","author":"Khosroyani","year":"2023","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104747_bib69","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104747_bib70","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4143\/crt.2021.1019","article-title":"A single-arm, prospective, phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent salivary gland cancer","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res Treat. J. Korean Cancer Assoc."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib71","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1470-2045(15)00485-4","article-title":"The promise and challenges of rare cancer research","volume":"17","author":"Komatsubara","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104747_bib72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib73","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cncr.24745","article-title":"A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer","volume":"116","author":"Laurie","year":"2010","journal-title":"Cancer"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104747_bib74","article-title":"Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08\/KM11)","volume":"40","author":"Lee","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104747_bib75","article-title":"A feasibility and safety study of concurrent chemotherapy based on genetic testing in patients with high-risk salivary gland tumors","volume":"97","author":"Li","year":"2018","journal-title":"Med. (Baltim. )"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104747_bib76","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104747_bib77","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104747_bib78","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone acetate in patients with castration-resistant, androgen receptor\u2013expressing salivary gland cancer: a phase II trial","volume":"39","author":"Locati","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104747_bib79","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/hed.25891","article-title":"Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract","volume":"41","author":"Locati","year":"2019","journal-title":"Head. Neck"},{"key":"10.1016\/j.critrevonc.2025.104747_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1264287","article-title":"Current management and future challenges in salivary glands cancer","volume":"13","author":"Locati","year":"2023","journal-title":"Front Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104747_bib81","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/cncr.32754","article-title":"Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life","volume":"126","author":"Locati","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104747_bib82","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104747_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-080032","article-title":"Artificial intelligence tools for optimising recruitment and retention in clinical trials: a scoping review protocol","volume":"14","author":"Lu","year":"2024","journal-title":"BMJ Open"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104747_bib84","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02)","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104747_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594446","article-title":"Barriers and opportunities for implementation of outcome-based spread payments for high-cost, one-shot curative therapies","volume":"11","author":"Michelsen","year":"2020","journal-title":"Front Pharm."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104747_bib86","article-title":"A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent\/metastatic adenoid cystic carcinoma","volume":"41","author":"Mohamadpour","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.36401\/JIPO-23-X1","article-title":"Learning from failure: negative trials in oncology","volume":"6","author":"Nardo","year":"2023","journal-title":"J. Immunother. Precis Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104747_bib88","article-title":"Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): the results of phase 2 study of darolutamide monotherapy","volume":"41","author":"Okano","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104747_bib89","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104747_bib90","article-title":"A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104747_bib91","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104747_bib92","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.ijrobp.2024.01.023","article-title":"Phase I\/II study of a novel MDM-2 Inhibitor (APG-115-Alrizomadlin) in p53 Wild Type Salivary Gland Cancers","volume":"118","author":"Pearson","year":"2024","journal-title":"Int J. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104747_bib93","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","article-title":"A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands","volume":"43","author":"Pfeffer","year":"2007","journal-title":"Oral. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104747_bib94","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40265-023-01879-4","article-title":"Results from Expanded Access Programs: A Review of Academic Literature","volume":"83","author":"Polak","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2025.104747_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102697","article-title":"Salivary gland carcinoma: Towards a more personalised approach","volume":"124","author":"Rached","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104747_bib96","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/cancers14051133","article-title":"Evaluation of the clinical utility of genomic profiling to inform selection of clinical trial therapy in salivary gland cancer","volume":"14","author":"Rack","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104747_bib97","unstructured":"R: The R Project for Statistical Computing. Accessed September 15, 2024. \u3008https:\/\/www.r-project.org\/\u3009."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104747_bib98","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/hed.25020","article-title":"Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies","volume":"40","author":"Rodriguez","year":"2018","journal-title":"Head. Neck"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104747_bib99","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamaoncol.2022.3161","article-title":"Optimizing histology-specific clinical trials in soft-tissue sarcoma\u2014are we there yet?","volume":"8","author":"Roland","year":"2022","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104747_bib100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.27252","article-title":"Participation of lower and upper middle\u2013income countries in clinical trials led by high-income countries","volume":"5","author":"Rubagumya","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2025.104747_bib101","article-title":"Lutetium-177-PSMA","author":"van Ruitenbeek","year":"2024","journal-title":"Ther. Recurr. \/Metastatic Sali Gland Cancer.: A Phase 2 Pilot Study"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104747_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23367","article-title":"Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives","volume":"10","author":"Schettini","year":"2024","journal-title":"Heliyon"},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104747_bib103","article-title":"A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Schoenfeld","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104747_bib104","unstructured":"SEER*Explorer [Internet] Cancer.gov. Accessed December 26, 2023. Available from: \u3008https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html\u3009."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib105","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.4317\/medoral.26264","article-title":"Systemic therapies for salivary gland carcinomas: an overview of published clinical trials","volume":"29","author":"Silva","year":"2024","journal-title":"Med Oral. Patol. Oral. Cirugia Bucal"},{"key":"10.1016\/j.critrevonc.2025.104747_bib106","article-title":"Disentangling trust of patients with rare cancer in their healthcare professionals and the healthcare system: a qualitative interview study","author":"Simons","year":"2024","journal-title":"J. Cancer Surviv"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104747_bib107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/gcc.23020","article-title":"Fusion-positive salivary gland carcinomas","volume":"61","author":"Sk\u00e1lov\u00e1","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100398","article-title":"Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations","volume":"7","author":"Solomon","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104747_bib109","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104747_bib110","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104747_bib111","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104747_bib112","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib113","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck","volume":"37","author":"Thomson","year":"2015","journal-title":"Head. Neck"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104747_bib114","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","article-title":"Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors","volume":"27","author":"Wong","year":"2016","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104747_bib115","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/hed.26719","article-title":"Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11-year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts","volume":"43","author":"Xu","year":"2021","journal-title":"Head. Neck"},{"key":"10.1016\/j.critrevonc.2025.104747_bib116","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41523-023-00522-5","article-title":"Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours","volume":"9","author":"Zhang","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.104747_bib117","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211013626","article-title":"Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study","volume":"13","author":"Zhu","year":"2021","journal-title":"Ther. Adv. Med Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104747_bib118","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1007\/s00405-023-08110-w","article-title":"Salivary gland pathologies: evolution in classification and association with unique genetic alterations","volume":"280","author":"\u017burek","year":"2023","journal-title":"Eur. Arch. Otorhinolaryngol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:29:26Z","timestamp":1749486566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":118,"alternative-id":["S1040842825001350"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104747","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challenges","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104747"}}